Advancing BTK Inhibitors in MS: Insights from Clinical Trials and Early Safety Data

This episode, titled Advancing BTK Inhibitors in MS: Insights from Clinical Trials and Early Safety Data, features Kiranpal Sangha, PharmD, and Ryan Fuller, PharmD, discussing key learnings from evobrutinib trials and their implications for the development of other BTK inhibitors, as well as safety and efficacy findings from the HERCULES trial and how they inform clinical use and ongoing investigation of BTK inhibitors in MS.

The development of Bruton's tyrosine kinase inhibitors (BTKis) in multiple sclerosis (MS) has been informed by lessons learned from earlier clinical trials, including those evaluating evobrutinib. Evobrutinib studies provided key insights into optimal dosing, safety monitoring, and pharmacodynamic activity, highlighting both the potential efficacy of BTK inhibition in reducing disease activity and the importance of understanding off-target effects. These findings have guided the design and evaluation of next-generation BTKis, such as tolebrutinib and fenebrutinib, helping researchers anticipate potential challenges, refine trial endpoints, and optimize strategies for assessing both relapsing and progressive forms of MS.

The HERCULES trial, evaluating another BTKi, has further expanded understanding of this therapeutic class. Interim safety and efficacy data indicate that BTK inhibition can modulate both peripheral and central immune activity with a manageable safety profile. The trial demonstrated reductions in MRI lesion activity and favorable trends in markers of neuroinflammation, suggesting potential benefits beyond relapse control. Together, these studies underscore the promise of BTKis as a novel approach to addressing unmet needs in MS, particularly in targeting chronic neuroinflammation and progression independent of relapse activity. Ongoing trials will continue to refine the risk-benefit profile, inform optimal dosing strategies, and clarify the role of BTK inhibitors in long-term disease management.

Led by the moderator, the neurology pharmacists examine the following critical questions:

Which lessons were learned from the evobrutinib clinical trials for other BTKi’s under investigation such as tolebrutinib and fenebrutinib?

What have the safety and efficacy data demonstrated so far from the HERCULES trial?

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

In the next episode, Fenebrutinib and the Future Role of BTK Inhibitors in MS Treatment, panelists will continue their discussion on multiple sclerosis and highlight pharmacists’ perspectives on the topline phase 3 results for fenebrutinib and explores how BTK inhibitors may be integrated into MS treatment algorithms if approved by the FDA.